These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Interactions of fibroblasts, adipocytes and immunocompeent cells in the pathogenesis of endocrine ophthalmopathy]. Heufelder AE Acta Med Austriaca; 2001; 28(4):89-92. PubMed ID: 11593897 [TBL] [Abstract][Full Text] [Related]
5. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?]. Wall JR; Lahooti H Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104 [TBL] [Abstract][Full Text] [Related]
6. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy. Dik WA; Virakul S; van Steensel L Exp Eye Res; 2016 Jan; 142():83-91. PubMed ID: 26675405 [TBL] [Abstract][Full Text] [Related]
7. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy. Janssen JAMJL; Smith TJ Cells; 2021 Feb; 10(2):. PubMed ID: 33673340 [TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases? Wall JR; Lahooti H Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712 [TBL] [Abstract][Full Text] [Related]
11. Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves' disease with and without ophthalmopathy: correlation with clinical features. Gopinath B; Musselman R; Adams CL; Tani J; Beard N; Wall JR Thyroid; 2006 Oct; 16(10):967-74. PubMed ID: 17042681 [TBL] [Abstract][Full Text] [Related]
12. TSHR as a therapeutic target in Graves' disease. Smith TJ Expert Opin Ther Targets; 2017 Apr; 21(4):427-432. PubMed ID: 28127991 [TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies. Khoo TK; Bahn RS Thyroid; 2007 Oct; 17(10):1013-8. PubMed ID: 17935483 [TBL] [Abstract][Full Text] [Related]
15. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Wang Y; Smith TJ Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1735-48. PubMed ID: 24651704 [TBL] [Abstract][Full Text] [Related]
16. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients. van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A Thyroid; 2010 May; 20(5):535-44. PubMed ID: 20384487 [TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of Graves' orbitopathy: a 2010 update. Smith TJ J Endocrinol Invest; 2010 Jun; 33(6):414-21. PubMed ID: 20631493 [TBL] [Abstract][Full Text] [Related]
18. [Current understanding of pathogenesis of Graves ophthalmopathy]. Ando T; Eguchi K Nihon Rinsho; 2006 Dec; 64(12):2275-8. PubMed ID: 17154091 [TBL] [Abstract][Full Text] [Related]
19. Genetic immunization with mouse thyrotrophin hormone receptor plasmid breaks self-tolerance for a murine model of autoimmune thyroid disease and Graves' orbitopathy. Schlüter A; Horstmann M; Diaz-Cano S; Plöhn S; Stähr K; Mattheis S; Oeverhaus M; Lang S; Flögel U; Berchner-Pfannschmidt U; Eckstein A; Banga JP Clin Exp Immunol; 2018 Mar; 191(3):255-267. PubMed ID: 29058307 [TBL] [Abstract][Full Text] [Related]